Forte Biosciences, Inc. announced positive results from its FB102 double-blind placebo-controlled Phase 1b study in vitiligo. The company hosted a conference call on July 9, 2026, to review the clinical trial data presentation. Forte Biosciences, Inc. is a biotechnology company focused on developing therapeutic solutions for skin diseases.
